{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:05:01Z","timestamp":1788433501221,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10147-025-02948-2","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:43:30Z","timestamp":1768895010000},"page":"393-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular analysis of tumor recurrence using established cancer stem cell-line and drug discovery"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0285-2464","authenticated-orcid":false,"given":"Kiyotaka","family":"Nakano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Zaitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyoko","family":"Nishime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genta","family":"Nagae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Harimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Natsugoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachie","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Aburatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsumi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"3","key":"2948_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"2948_CR2","unstructured":"Center for Cancer Control and Information Services NCC, Japan, (2023) Cancer Statistics in Japan 2023. Tokyo"},{"issue":"23","key":"2948_CR3","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343\u20132351. https:\/\/doi.org\/10.1056\/NEJMoa032709","journal-title":"N Engl J Med"},{"issue":"35","key":"2948_CR4","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1200\/jco.2015.63.4238","volume":"33","author":"T Andr\u00e9","year":"2015","unstructured":"Andr\u00e9 T, de Gramont A, Vernerey D et al (2015) Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 33(35):4176\u20134187. https:\/\/doi.org\/10.1200\/jco.2015.63.4238","journal-title":"J Clin Oncol"},{"issue":"1","key":"2948_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23922\/jarc.2022-102","volume":"7","author":"Y Hashiguchi","year":"2023","unstructured":"Hashiguchi Y, Muro K, Saito Y et al (2023) JSCCR guidelines 2022 for the treatment of colorectal cancer. J Anus Rectum Colon 7(1):1\u201328. https:\/\/doi.org\/10.23922\/jarc.2022-102","journal-title":"J Anus Rectum Colon"},{"issue":"1","key":"2948_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1758834015614530","volume":"8","author":"WA Hammond","year":"2016","unstructured":"Hammond WA, Swaika A, Mody K (2016) Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol 8(1):57\u201384. https:\/\/doi.org\/10.1177\/1758834015614530","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"2948_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani D, Oki E, Nakamura Y et al (2023) Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 29(1):127\u2013134. https:\/\/doi.org\/10.1038\/s41591-022-02115-4","journal-title":"Nat Med"},{"issue":"1","key":"2948_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","volume":"9","author":"J He","year":"2024","unstructured":"He J, Qiu Z, Fan J et al (2024) Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies. Signal Transduct Target Ther 9(1):209. https:\/\/doi.org\/10.1038\/s41392-024-01891-4","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2948_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu X, Tian W, Ning J et al (2024) Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Ther 9(1):170. https:\/\/doi.org\/10.1038\/s41392-024-01851-y","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"2948_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle E, Clevers H (2017) Cancer stem cells revisited. Nat Med 23(10):1124\u20131134. https:\/\/doi.org\/10.1038\/nm.4409","journal-title":"Nat Med"},{"issue":"19","key":"2948_CR11","doi-asserted-by":"publisher","first-page":"9339","DOI":"10.1158\/0008-5472.Can-06-3126","volume":"66","author":"MF Clarke","year":"2006","unstructured":"Clarke MF, Dick JE, Dirks PB et al (2006) Cancer stem cells\u2013perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66(19):9339\u20139344. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-3126","journal-title":"Cancer Res"},{"issue":"7123","key":"2948_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature05372","volume":"445","author":"CA O'Brien","year":"2007","unstructured":"O\u2019Brien CA, Pollett A, Gallinger S et al (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106\u2013110. https:\/\/doi.org\/10.1038\/nature05372","journal-title":"Nature"},{"issue":"3","key":"2948_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2011.01.038","volume":"19","author":"T Ishimoto","year":"2011","unstructured":"Ishimoto T, Nagano O, Yae T et al (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19(3):387\u2013400. https:\/\/doi.org\/10.1016\/j.ccr.2011.01.038","journal-title":"Cancer Cell"},{"issue":"8","key":"2948_CR14","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1158\/0008-5472.Can-08-4418","volume":"69","author":"EH Huang","year":"2009","unstructured":"Huang EH, Hynes MJ, Zhang T et al (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69(8):3382\u20133389. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-4418","journal-title":"Cancer Res"},{"issue":"7165","key":"2948_CR15","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/nature06196","volume":"449","author":"N Barker","year":"2007","unstructured":"Barker N, van Es JH, Kuipers J et al (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449(7165):1003\u20131007. https:\/\/doi.org\/10.1038\/nature06196","journal-title":"Nature"},{"issue":"7229","key":"2948_CR16","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/nature07602","volume":"457","author":"N Barker","year":"2009","unstructured":"Barker N, Ridgway RA, van Es JH et al (2009) Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457(7229):608\u2013611. https:\/\/doi.org\/10.1038\/nature07602","journal-title":"Nature"},{"issue":"3","key":"2948_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nm.3802","volume":"21","author":"M Matano","year":"2015","unstructured":"Matano M, Date S, Shimokawa M et al (2015) Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med 21(3):256\u2013262. https:\/\/doi.org\/10.1038\/nm.3802","journal-title":"Nat Med"},{"issue":"314","key":"2948_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac7433","volume":"7","author":"MR Junttila","year":"2015","unstructured":"Junttila MR, Mao W, Wang X et al (2015) Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer. Sci Transl Med 7(314):314ra186. https:\/\/doi.org\/10.1126\/scitranslmed.aac7433","journal-title":"Sci Transl Med"},{"issue":"12","key":"2948_CR19","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1002\/stem.1257","volume":"30","author":"S Kobayashi","year":"2012","unstructured":"Kobayashi S, Yamada-Okabe H, Suzuki M et al (2012) LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 30(12):2631\u20132644. https:\/\/doi.org\/10.1002\/stem.1257","journal-title":"Stem Cells"},{"issue":"5","key":"2948_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1267\/ahc.15019","volume":"48","author":"M Yamazaki","year":"2015","unstructured":"Yamazaki M, Kato A, Zaitsu Y et al (2015) Intensive immunofluorescence staining methods for low expression protein: detection of intestinal stem cell marker LGR5. Acta Histochem Cytochem 48(5):159\u2013164. https:\/\/doi.org\/10.1267\/ahc.15019","journal-title":"Acta Histochem Cytochem"},{"issue":"1","key":"2948_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41374-020-0471-y","volume":"101","author":"M Yamazaki","year":"2021","unstructured":"Yamazaki M, Kato A, Oki E et al (2021) Continuous formation of small clusters with LGR5-positive cells contributes to tumor growth in a colorectal cancer xenograft model. Lab Invest 101(1):12\u201325. https:\/\/doi.org\/10.1038\/s41374-020-0471-y","journal-title":"Lab Invest"},{"issue":"7467","key":"2948_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature12624","volume":"501","author":"CE Meacham","year":"2013","unstructured":"Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature 501(7467):328\u2013337. https:\/\/doi.org\/10.1038\/nature12624","journal-title":"Nature"},{"issue":"9","key":"2948_CR23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.Cd-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Amant F, Biankin AV et al (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4(9):998\u20131013. https:\/\/doi.org\/10.1158\/2159-8290.Cd-14-0001","journal-title":"Cancer Discov"},{"issue":"6","key":"2948_CR24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler JJ, Tan AC, Weekes CD et al (2012) Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9(6):338\u2013350. https:\/\/doi.org\/10.1038\/nrclinonc.2012.61","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2948_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-023-00433-y","volume":"12","author":"Z Fang","year":"2023","unstructured":"Fang Z, Li P, Du F et al (2023) The role of organoids in cancer research. Exp Hematol Oncol 12(1):69. https:\/\/doi.org\/10.1186\/s40164-023-00433-y","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2948_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1186\/s12967-024-05824-1","volume":"22","author":"G Zeng","year":"2024","unstructured":"Zeng G, Yu Y, Wang M et al (2024) Advancing cancer research through organoid technology. J Transl Med 22(1):1007. https:\/\/doi.org\/10.1186\/s12967-024-05824-1","journal-title":"J Transl Med"},{"issue":"9","key":"2948_CR27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1440-1827.2008.02271.x","volume":"58","author":"E Fujii","year":"2008","unstructured":"Fujii E, Suzuki M, Matsubara K et al (2008) Establishment and characterization of in vivo human tumor models in the NOD\/SCID\/gamma(c)(null) mouse. Pathol Int 58(9):559\u2013567. https:\/\/doi.org\/10.1111\/j.1440-1827.2008.02271.x","journal-title":"Pathol Int"},{"issue":"1","key":"2948_CR28","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1038\/s41598-020-60145-9","volume":"10","author":"S Kawai","year":"2020","unstructured":"Kawai S, Yamazaki M, Shibuya K et al (2020) Three-dimensional culture models mimic colon cancer heterogeneity induced by different microenvironments. Sci Rep 10(1):3156. https:\/\/doi.org\/10.1038\/s41598-020-60145-9","journal-title":"Sci Rep"},{"issue":"9","key":"2948_CR29","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nrc1694","volume":"5","author":"T Brabletz","year":"2005","unstructured":"Brabletz T, Jung A, Spaderna S et al (2005) Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744\u2013749. https:\/\/doi.org\/10.1038\/nrc1694","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2948_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrc.2018.1","volume":"18","author":"I Zlobec","year":"2018","unstructured":"Zlobec I, Lugli A (2018) Tumour budding in colorectal cancer: molecular rationale for clinical translation. Nat Rev Cancer 18(4):203\u2013204. https:\/\/doi.org\/10.1038\/nrc.2018.1","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2948_CR31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/his.14128","volume":"77","author":"S Shivji","year":"2020","unstructured":"Shivji S, Conner JR, Barresi V et al (2020) Poorly differentiated clusters in colorectal cancer: a current review and implications for future practice. Histopathology 77(3):351\u2013368. https:\/\/doi.org\/10.1111\/his.14128","journal-title":"Histopathology"},{"issue":"7653","key":"2948_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nature22081","volume":"545","author":"M Shimokawa","year":"2017","unstructured":"Shimokawa M, Ohta Y, Nishikori S et al (2017) Visualization and targeting of LGR5(+) human colon cancer stem cells. Nature 545(7653):187\u2013192. https:\/\/doi.org\/10.1038\/nature22081","journal-title":"Nature"},{"issue":"6","key":"2948_CR33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.stem.2020.04.012","volume":"26","author":"C Morral","year":"2020","unstructured":"Morral C, Stanisavljevic J, Hernando-Momblona X et al (2020) Zonation of ribosomal DNA transcription defines a stem cell hierarchy in colorectal cancer. Cell Stem Cell 26(6):845-861.e812. https:\/\/doi.org\/10.1016\/j.stem.2020.04.012","journal-title":"Cell Stem Cell"},{"issue":"3","key":"2948_CR34","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E et al (2020) A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 20(3):174\u2013186. https:\/\/doi.org\/10.1038\/s41568-019-0238-1","journal-title":"Nat Rev Cancer"},{"key":"2948_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1618742","volume":"16","author":"C Qian","year":"2025","unstructured":"Qian C, Ren L, Zhu S et al (2025) Current perspectives and trends in colorectal cancer and cancer-associated fibroblasts: a review and bibliometric analysis. Front Immunol 16:1618742. https:\/\/doi.org\/10.3389\/fimmu.2025.1618742","journal-title":"Front Immunol"},{"issue":"10","key":"2948_CR36","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","volume":"24","author":"M Russo","year":"2024","unstructured":"Russo M, Chen M, Mariella E et al (2024) Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat Rev Cancer 24(10):694\u2013717. https:\/\/doi.org\/10.1038\/s41568-024-00737-z","journal-title":"Nat Rev Cancer"},{"key":"2948_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1612089","volume":"16","author":"H Li","year":"2025","unstructured":"Li H, Xu W, Cheng W et al (2025) Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies. Front Pharmacol 16:1612089. https:\/\/doi.org\/10.3389\/fphar.2025.1612089","journal-title":"Front Pharmacol"},{"issue":"8","key":"2948_CR38","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41568-025-00824-9","volume":"25","author":"A Soragni","year":"2025","unstructured":"Soragni A, Knudsen ES, O\u2019Connor TN et al (2025) Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer 25(8):613\u2013633. https:\/\/doi.org\/10.1038\/s41568-025-00824-9","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2948_CR39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","volume":"184","author":"SK Rehman","year":"2021","unstructured":"Rehman SK, Haynes J, Collignon E et al (2021) Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell 184(1):226-242.e221. https:\/\/doi.org\/10.1016\/j.cell.2020.11.018","journal-title":"Cell"},{"issue":"9","key":"2948_CR40","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s43018-022-00402-0","volume":"3","author":"A \u00c1lvarez-Varela","year":"2022","unstructured":"\u00c1lvarez-Varela A, Novellasdemunt L, Barriga FM et al (2022) Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. Nat Cancer 3(9):1052\u20131070. https:\/\/doi.org\/10.1038\/s43018-022-00402-0","journal-title":"Nat Cancer"},{"issue":"1","key":"2948_CR41","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41420-025-02567-w","volume":"11","author":"K Nakano","year":"2025","unstructured":"Nakano K, Oki E, Yamazaki M et al (2025) Colorectal cancer cell line-derived organoid model with stem cell properties captures the regrowing state of residual cancer cells after neoadjuvant chemotherapy. Cell Death Discov 11(1):282. https:\/\/doi.org\/10.1038\/s41420-025-02567-w","journal-title":"Cell Death Discov"},{"key":"2948_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105532","volume":"167","author":"K Shah","year":"2021","unstructured":"Shah K, Panchal S, Patel B (2021) Porcupine inhibitors: novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway. Pharmacol Res 167:105532. https:\/\/doi.org\/10.1016\/j.phrs.2021.105532","journal-title":"Pharmacol Res"},{"key":"2948_CR43","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2022.5472","author":"Y Chen","year":"2023","unstructured":"Chen Y, Chen M, Deng K (2023) Blocking the Wnt\/\u03b2\u2011catenin signaling pathway to treat colorectal cancer: strategies to improve current therapies (Review). Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2022.5472","journal-title":"Int J Oncol"},{"issue":"4","key":"2948_CR44","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3892\/ijo.2016.3360","volume":"48","author":"X Wu","year":"2016","unstructured":"Wu X, Luo F, Li J et al (2016) Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon cancer cell lines via inhibition of the Wnt signaling pathway. Int J Oncol 48(4):1333\u20131340. https:\/\/doi.org\/10.3892\/ijo.2016.3360","journal-title":"Int J Oncol"},{"key":"2948_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cells14151207","author":"M Nigam","year":"2025","unstructured":"Nigam M, Punia B, Dimri DB et al (2025) Reactive oxygen species: a double-edged sword in the modulation of cancer signaling pathway dynamics. Cells. https:\/\/doi.org\/10.3390\/cells14151207","journal-title":"Cells"},{"issue":"8","key":"2948_CR46","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","volume":"23","author":"C Glorieux","year":"2024","unstructured":"Glorieux C, Liu S, Trachootham D et al (2024) Targeting ROS in cancer: rationale and strategies. Nat Rev Drug Discov 23(8):583\u2013606. https:\/\/doi.org\/10.1038\/s41573-024-00979-4","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2948_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2014.11.019","volume":"27","author":"IS Harris","year":"2015","unstructured":"Harris IS, Treloar AE, Inoue S et al (2015) Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27(2):211\u2013222. https:\/\/doi.org\/10.1016\/j.ccell.2014.11.019","journal-title":"Cancer Cell"},{"key":"2948_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225544","author":"RQ Jacobs","year":"2022","unstructured":"Jacobs RQ, Fuller KB, Cooper SL et al (2022) RNA polymerase I is uniquely vulnerable to the small-molecule inhibitor BMH-21. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14225544","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2948_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16393-4","volume":"11","author":"E Sanij","year":"2020","unstructured":"Sanij E, Hannan KM, Xuan J et al (2020) CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nat Commun 11(1):2641. https:\/\/doi.org\/10.1038\/s41467-020-16393-4","journal-title":"Nat Commun"},{"key":"2948_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020266","author":"R Ferreira","year":"2020","unstructured":"Ferreira R, Schneekloth JS Jr., Panov KI et al (2020) Targeting the RNA polymerase I transcription for cancer therapy comes of age. Cells. https:\/\/doi.org\/10.3390\/cells9020266","journal-title":"Cells"},{"issue":"2","key":"2948_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2217\/pme-2020-0099","volume":"18","author":"A Zalewski","year":"2021","unstructured":"Zalewski A, Snook AE, Waldman SA (2021) Stem cells as therapeutic targets in colorectal cancer. Per Med 18(2):171\u2013183. https:\/\/doi.org\/10.2217\/pme-2020-0099","journal-title":"Per Med"},{"key":"2948_CR52","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.semcancer.2021.02.012","volume":"82","author":"L Du","year":"2022","unstructured":"Du L, Cheng Q, Zheng H et al (2022) Targeting stemness of cancer stem cells to fight colorectal cancers. Semin Cancer Biol 82:150\u2013161. https:\/\/doi.org\/10.1016\/j.semcancer.2021.02.012","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"2948_CR53","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1039\/d4md00122b","volume":"15","author":"SU Zaman","year":"2024","unstructured":"Zaman SU, Pagare PP, Ma H et al (2024) Novel PROTAC probes targeting KDM3 degradation to eliminate colorectal cancer stem cells through inhibition of Wnt\/\u03b2-catenin signaling. RSC Med Chem 15(11):3746\u20133758. https:\/\/doi.org\/10.1039\/d4md00122b","journal-title":"RSC Med Chem"},{"issue":"7924","key":"2948_CR54","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41586-022-05043-y","volume":"608","author":"Y Ohta","year":"2022","unstructured":"Ohta Y, Fujii M, Takahashi S et al (2022) Cell-matrix interface regulates dormancy in human colon cancer stem cells. Nature 608(7924):784\u2013794. https:\/\/doi.org\/10.1038\/s41586-022-05043-y","journal-title":"Nature"},{"key":"2948_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-025-01913-4","author":"L Leak","year":"2025","unstructured":"Leak L, Wang Z, Joseph AJ et al (2025) Tegavivint triggers TECR-dependent nonapoptotic cancer cell death. Nat Chem Biol. https:\/\/doi.org\/10.1038\/s41589-025-01913-4","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2948_CR56","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clcc.2022.11.002","volume":"22","author":"MA Shah","year":"2023","unstructured":"Shah MA, Yoshino T, Tebbutt NC et al (2023) Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III CanStem303C study. Clin Colorectal Cancer 22(1):100\u2013110. https:\/\/doi.org\/10.1016\/j.clcc.2022.11.002","journal-title":"Clin Colorectal Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02948-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02948-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02948-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:03:27Z","timestamp":1771952607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02948-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2948"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02948-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.N., M.Y., S.K. are employees of Chugai Pharmaceutical Co., Ltd. M.S. and C.N are employees of Central Institute for Experimental Medicine and Life Science. T.Y. is a board member of Central Institute for Experimental Medicine and Life Science. E.O. reports research funding from Guardant Health, and honoraria from Ono, Takeda, Eli Lilly and Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not require ethical approval because it was a review of published articles and did not directly involve human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}